|
Patent landscape, scope, and claims: |
Scope and US patent landscape for microparticulate, delayed-and-controlled release “reservoir” microcapsules with dual pH/time-triggered mechanisms (US Patent 8,101,209)
Executive summary: US Patent 8,101,209 claims a narrow, engineering-defined oral controlled-release platform: reservoir microcapsules (200 to 800 microns) with a single composite coating film containing an ionizable hydrophilic polymer A plus a hydrophobic compound B (specific lipid/wax list) with B/A weight ratio 0.5 to 1.5, and dual triggering where (i) pH variation drives release and (ii) a residence-time trigger in the stomach releases after a predetermined time. The dissolution behavior at pH 1.4 includes a latency phase ≤5 hours followed by controlled release with t1/2 0.5 to 35 hours, and when moving to pH 6.8 the release starts without latency. Dependent claims tighten parameters (latency 1 to 5 hours; coating film ≤40 wt%; B/A 0.5 to 1.0; polymer A and hydrophobic B sublists; talc-free). The claim set is strong on formulation architecture and dissolution signatures, but weak for broad drug coverage because it excludes perindopril and defines a platform that must match the specified microcapsule size, coating composition ratios, and in vitro dissolution timelines.
What does US Patent 8,101,209 claim for delayed and controlled release microparticulate oral dosage forms?
Core claim 1 (platform definition): A microparticulate oral dosage form for delayed and controlled release of at least one active principle (AP) (excluding perindopril) with absorption limited to upper GI parts, comprising:
- Reservoir microcapsules of active principle.
- Each microcapsule has one single, composite coating film.
- The coating film has:
- Hydrophilic polymer A with ionizable groups at neutral pH.
- Hydrophobic compound B from a specified list.
- Microcapsule diameter: 200–800 µm.
- Weight ratio B/A: 0.5–1.5.
- Two release triggering mechanisms:
- pH-triggered release due to pH variation.
- time-in-stomach trigger after predetermined residence time.
- In vitro dissolution requirements:
- At pH 1.4: latency phase ≤5 hours, then controlled release.
- After latency: t1/2 (0.5–35 hours).
- When switching pH 1.4 to 6.8: release phase starts without latency.
Dependent claims (scope narrowing levers):
- Claim 2: latency 1–5 hours.
- Claim 3: coating film mass fraction ≤40 wt% (of microcapsules).
- Claim 4: B/A 0.5–1.0.
- Claims 5–6: polymer A species restricted to specific (meth)acrylic/cellulose phthalate/succinate candidates.
- Claims 7–8: hydrophobic B narrowed to specific hydrogenated oils/waxes and triglyceride glycerides.
- Claim 9: coating film talc-free.
- Claim 10: pH shift release without latency with t1/2 0.5–20 h.
- Claims 11–13: active on neutral core 200–600 µm; core sugar excipient (sucrose/dextrose/lactose); core material may be cellulose microsphere.
- Claims 14–15: active principle exemplars cover many therapeutic classes; claim set remains platform-limited (perindopril excluded by claim 1).
- Claim 16: dosage form is tablet, powder, or capsule.
- Claim 17: tablet disperses in the mouth.
Claim interpretation hotspots (what determines infringement/design-around)
- Dual-trigger mechanism: must be engineered so that both (i) pH variation causes release and (ii) a predetermined stomach residence time governs release. If a competitor’s system lacks a second time-dependent mechanism, claim 1 is at risk.
- Dissolution signature coupling: the claim does not merely require “delayed release,” it requires specific latency duration at pH 1.4 and t1/2 ranges plus a latency-free restart at pH 6.8. That ties infringement to testing outcomes.
- Single composite coating film: if a competitor uses multilayer coatings or different film architecture (separate layers for hydrophilic vs hydrophobic components), they may avoid literal scope.
- B/A ratio and microcapsule size: both are numeric constraints.
- Exclusion: perindopril is excluded, which can matter for any perindopril platform variants.
What is the technical claim scope in terms of microcapsule size, coatings, and polymer selections?
Microcapsule size and core architecture
- Microcapsule diameter: 200–800 µm (claim 1).
- Neutral core diameter (dependent): 200–600 µm (claim 11).
- Neutral core excipients (dependent): sucrose/dextrose/lactose (claim 12).
- Neutral core material (dependent): cellulose microsphere (claim 13).
Practical implication: a design using different inert cores (non-sugar, different particle size distribution) may avoid dependent coverage, and potentially independent coverage if it affects the final microcapsule size range or reservoir geometry.
Composite coating film design: hydrophilic polymer A + hydrophobic B
Hydrophilic polymer A candidates (dependent):
- (meth)acrylic acid polymers
- alkyl (meth)acrylate polymers
- (meth)acrylic acid/alkyl (meth)acrylate copolymers
- cellulose derivatives
- cellulose acetate phthalate (CAP)
- hydroxypropyl methyl cellulose phthalate (HPMCP)
- hydroxypropyl methyl cellulose acetate succinate (HPMCAS)
(claim 5)
Tighter subset (dependent):
- (meth)acrylic acid/methyl(meth)acrylate copolymers
- CAP
- HPMCP
- HPMCAS
(claim 6)
Hydrophobic compound B (claim 1 by general list) with tighter subset (claims 7–8):
- hydrogenated vegetable oils and waxes including hydrogenated cottonseed/soybean/palm oils
- glyceryl behenate
- hydrogenated castor oil
- Carnauba wax
- tristearin, tripalmitin, trimyristin
- glyceryl palmitostearate
(claim 7)
and subset repetition (claim 8)
Ratio constraints:
- claim 1: B/A 0.5–1.5
- claim 4: B/A 0.5–1.0
Practical implication: even if a competitor chooses the same polymer class, substitution of hydrophobic components outside the listed families or shifting the B/A ratio outside the numeric window is a straightforward carve-out.
Coating film composition amount and talc restriction
- Coating film wt%: ≤40 wt% (claim 3).
- Talc-free coating film: (claim 9).
How do the dissolution and dual-trigger requirements define the “release timing” boundaries for infringement?
In vitro dissolution at pH 1.4 (required)
At constant pH 1.4:
- Latency phase duration: ≤5 hours (claim 1)
- dependent tightening: 1–5 hours (claim 2)
- Following latency: controlled release with t1/2 0.5–35 hours (claim 1)
- Another dependent: when release starts without latency after pH shift (claim 10) t1/2 0.5–20 hours
pH shift behavior (required)
- Change pH 1.4 → 6.8: release phase starts without latency (claim 1)
- and in that no-latency phase the t1/2 is 0.5–20 h (claim 10)
Engineering meaning: the system must be stable enough to hold drug during an acidic latency window, then “wake up” upon neutral pH without additional delay. The presence of ionizable hydrophilic polymer A at neutral pH combined with hydrophobic B is the mechanism posited by the claim language.
Dual triggering mechanism definition
- Mechanism 1: pH variation triggers release.
- Mechanism 2: after a predetermined residence time in the stomach, release occurs.
Key enforcement point: if prosecution history or spec includes one trigger as predominant and the other as incidental, the claim still reads on systems that exhibit both within the claimed dissolution performance. For litigation, the testing method and the mapping of “predetermined residence time” to measurable in vitro proxies becomes central.
Which active principles are covered by US Patent 8,101,209, and what is excluded?
Exclusion
- Perindopril is excluded by claim 1.
Active principle examples (claim 14–15)
Claim 14 lists classes; claim 15 lists exemplars including:
- anti-ulcer agents: omeprazole, cimetidine, famotidine, ranitidine
- antidiabetics: metformin
- anticoagulants/antithrombics/antiplatelets: aspirin (acetylsalicylic acid)
- cardiovascular: prazosin, nifedipine, diltiazem, metoprolol, captopril, nicardipine, quinidine, simvastatin, spironolactone
- antivirals: acyclovir, zidovudine, famciclovir
- anti-inflammatories/NSAIDs: naproxen, ibuprofen, flurbiprofen, flurbiprofen-like entries in the list
- psych: fluoxetine, alprazolam
- CNS/pain: morphine, pentazocine, paracetamol
- others: ketoprofen, indomethacin, diclofenac, carbamazepine, enalaprin, tams not listed (only the listed ones apply)
- 5-ASA: 5-asa
Practical impact: the list is broad, but the platform constraints are narrower than the API universe. Any generic or branded product that uses the same microparticle coating system should be assessed as a platform case, not an API-specific case.
What US Orange Book status and FDA pathway interactions are relevant to this patent estate?
No Orange Book entries or FDA product-page listings are provided in the input, and US Patent 8,101,209 cannot be mapped to specific marketed drug products without knowing the patent’s corresponding Orange Book reference listed drug (RLD) or the patent’s assignee/jurisdiction-specific bibliographic data.
Accordingly, the analysis cannot correctly determine:
- which RLD(s) list US 8,101,209 in the Orange Book,
- whether it is for drug substance, drug product, or method-of-use,
- whether FDA submissions triggered 505(b)(2), ANDA, or Paragraph IV certifications.
Where does US 8,101,209 sit in the broader patent landscape for controlled-release GI-triggered microcapsules?
What the claim language implies about “technology family” clustering
The claim is unusually specific in three dimensions that typically cluster within a technology family:
- Reservoir microcapsules with single composite film using defined polymer/hydrophobic pairings.
- Dual triggering that blends pH-dependent release and residence-time dependent activation.
- Tested dissolution signature at pH 1.4 with latency and t1/2 windows and a no-latency pH shift restart at pH 6.8.
Landscape inference: competitor systems in this space usually differentiate by:
- using different coating polymers outside the listed CAP/HPMCP/HPMCAS or the specific (meth)acrylic/cellulose derivative set,
- using different lipid/hydrophobic excipients not in the listed wax/oil/triglyceride classes,
- switching to different microcapsule size distributions,
- changing B/A ratios,
- implementing multilayer coatings or distinct barrier layers rather than a single composite film,
- or failing the exact latency and t1/2 in vitro profile.
Likely claim-coverage “pressure points” for competitors
- pH shift without latency: is the most litigious “fingerprint” requirement. Many delayed-release systems still show some transition delay after pH change.
- Residency time trigger: is harder to validate and can become a key non-infringement argument if a competitor’s system relies only on pH or only on diffusion kinetics.
How strong is the patent estate for US 8,101,209 based on claim breadth and vulnerability?
Strengths
- Numerical constraints (diameters, B/A ratio, latency durations, t1/2 windows) reduce ambiguity and can support clean testing-based infringement proof.
- Material-limited composition (explicit lists for B and A families) provides concrete boundaries.
- Distinct dissolution signature plus no-latency restart at pH 6.8 creates a strong technical differentiator.
Vulnerabilities / common non-infringement paths
- Substitution outside lists: alternate hydrophobic components not in the enumerated groups, even if functionally similar.
- Ratio drift: B/A outside 0.5–1.5 (or 0.5–1.0 for dependent coverage).
- Architecture differences: multi-layer films, or non-composite structures.
- Dissolution profile mismatch: if measured latency at pH 1.4 exceeds 5 hours or if t1/2 falls outside claimed windows, or if pH shift shows latency.
- Perindopril carve-out limits enforcement for that API.
Litigation readiness
The claim reads like an infringement-ready engineering spec. If a plaintiff can obtain:
- microcapsule characterization (size, coating ratio, composite film presence),
- and dissolution testing under defined conditions,
the patent offers a structured case rather than relying on broad functional language.
What generic entry risks exist for this platform in the US?
Because the claim binds to a tightly defined formulation system and dissolution behavior, generic entry risk is driven by whether ANDA (or 505(b)(2) competitor) formulations are built on the same microcapsule platform.
Two risk scenarios:
- Higher risk: a generic uses reservoir microcapsules (200–800 µm) with single composite film containing an ionizable hydrophilic polymer A and listed hydrophobic B, at B/A in claimed ranges, and matches latency/t1/2 and pH-shift behavior.
- Lower risk: a generic implements alternative coating compositions, different hydrophobic excipients, different particle size, altered film mass fraction, or changes dissolution signature (even if overall “delayed release” is achieved).
No product-specific scenario can be assigned to a named competitor without bibliographic mapping to RLDs and Orange Book listings, which are not provided.
What claim design-arounds are most plausible under the literal claim language?
- Remove dual-trigger behavior by designing a system where release is only pH-driven or only time-driven.
- Use hydrophobic compound B not in the listed categories (or change the material even within “fatty” classes).
- Adjust B/A ratio outside 0.5–1.5 (and for a tighter target, outside 0.5–1.0).
- Change microcapsule size distribution so the product falls outside 200–800 µm or (if targeting dependent claims) 200–600 µm neutral core.
- Use a different coating architecture than a single composite film (e.g., layered film structure).
- Fail the dissolution fingerprint: build a system where pH 1.4 latency exceeds 5 hours, or where pH shift to 6.8 still shows latency, or where t1/2 falls outside 0.5–35 h (or 0.5–20 h in the no-latency phase).
What about method-of-use, formulation, and manufacturing claim coverage beyond claim 1?
From the provided claim text:
- The claims are framed as a pharmaceutical dosage form defined by composition, structure, and dissolution performance. That is closer to formulation/product coverage than a classic method-of-use.
- There are no explicit process parameters (e.g., microencapsulation temperatures, coating process steps) in the provided claim set, meaning manufacturing-process barriers are not captured in the claims shown.
- Dependent claims focus on microcapsule architecture and excipient selections, not on manufacturing.
Accordingly, enforcement is likely to target the resulting dosage form and its in vitro performance, rather than a method.
Key Takeaways
- US Patent 8,101,209 claims a specific reservoir microcapsule oral delayed/controlled-release platform with single composite coating combining an ionizable hydrophilic polymer A and a listed hydrophobic compound B.
- The claim is bounded by hard numeric constraints: microcapsule diameter 200–800 µm, B/A 0.5–1.5, coating film ≤40 wt% (dependent), and strict dissolution fingerprints at pH 1.4 (latency ≤5 h; t1/2 0.5–35 h) and after pH shift to 6.8 (no latency; dependent t1/2 0.5–20 h).
- Perindopril is excluded, narrowing API-specific enforcement.
- Competitive risk hinges on whether rivals match both composition boundaries and dissolution behavior. Design-arounds that change hydrophobic selection, B/A ratio, coating architecture, particle size, or pH-shift dissolution signature are most directly aligned to non-infringement.
FAQs
1) Does claim 1 require that the active principle absorption be limited to the upper GI tract?
Yes. Claim 1 includes the functional limitation that absorption is essentially limited to the upper parts of the gastrointestinal tract.
2) What happens to coverage if a formulation has pH-triggered release but no stomach-residence-time trigger?
Claim 1 requires two triggering mechanisms, including a predetermined residence-time trigger in the stomach.
3) Can a competitor use a different hydrophobic excipient that is not in the listed B groups?
Literal coverage is constrained to the enumerated hydrophobic B selections (with listed mixtures), so an out-of-list excipient is a straightforward avoidance route.
4) Is talc allowed in the coating film?
Claim 9 restricts talc in the coating film; talc presence would defeat dependent claim 9 but may still be assessed for claim 1 unless talc affects other required parameters.
5) Does the claim cover any delayed-release tablet, or only those matching the specified dissolution latency and t1/2 windows?
Only those matching the specified in vitro dissolution fingerprint at pH 1.4 (latency ≤5 h; t1/2 0.5–35 h) and no-latency restart upon shifting to pH 6.8.
References (APA)
- United States Patent 8,101,209.
More… ↓
⤷ Start Trial
|
